
NASDAQ:VRTX
This summary was created by AI, based on 1 opinions in the last 12 months.
Vertex Pharmaceuticals Inc. (VRTX-Q) has garnered praise for its innovative approaches in the development of treatments for cystic fibrosis, positioning its drugs as the new standard of care in this area. Additionally, the company's work in gene therapies is noted for its cutting-edge science, placing Vertex at the forefront of advancements in biopharmaceuticals. Experts highlight the effectiveness of its therapies, which have significantly improved the quality of life for patients. Vertex's commitment to research and development reflects a strong potential for continued growth and influence in the healthcare sector. Overall, the company is seen as a leader in its field due to its pioneering research and successful drug portfolio.
Vertex Pharmaceuticals Inc. is a American stock, trading under the symbol VRTX (previously VRTX-Q on Stockchase) on the NASDAQ (VRTX). It is usually referred to as NASDAQ:VRTX or VRTX
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on VRTX (previously VRTX-Q on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is PARTIAL SELL. Read the latest stock experts' ratings for Vertex Pharmaceuticals Inc..
Vertex Pharmaceuticals Inc. was recommended as a Top Pick by Amy Raskin, CIO, Chevy Chase Trust on 2024-03-11. Read the latest stock experts ratings for Vertex Pharmaceuticals Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Vertex Pharmaceuticals Inc..
Vertex Pharmaceuticals Inc. is followed by 78 investors on Stockchase and is a trending stock that is worth watching.
On 2026-06-30, Vertex Pharmaceuticals Inc. (VRTX) stock closed at a price of $496.73.
Pharma is a great place to be now after being dormant. Vertex owns a cystic fibrosis channel and thriving in other therapeutic areas.